ClinicalTrials.gg
TerminatedNCT03618160Updated Feb 3, 2025

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

A Phase 1 interventional study of JNJ-64565111 and Placebo in Healthy, sponsored by Janssen Pharmaceutical K.K.. Terminated at 2 sites in Japan. Open to male participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Why this study was terminated
The results of leading Phase 2 trials did not meet all desired endpoints

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64565111 following single and multiple subcutaneous (SC) doses in healthy Japanese male participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Part 1 and Part 2, participant must be a Japanese male 20 to 65 years of age, inclusive, at the time of for screening. For Part 3, participant must be a Caucasian male (defined as white and all of his parents and grandparents are white as determined by participant's verbal report) 20 to 65 years of age, inclusive, at the time of informed consent for screening
  • Participant must agree to use an adequate method as deemed appropriate by the investigator; to always use a condom during sexual intercourse (even in case of prior vasectomy), or to remain abstinent, and not to donate sperm during the study and for 90 days after study drug administration. Participants should encourage their female partner to use an effective method of contraception (example, prescription oral contraceptives, contraceptive injections, intrauterine device, or contraceptive patch) in addition to the condom used by the male study participant
  • Participant must have a (BMI) ranging from 25 to 40 kilogram per meter square (kg/m\^2), weighing 120 kilogram (kg) or less
  • Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12 lead (ECG) performed at screening
  • Participant must be a non smoker for at least 1 month prior to screening. A positive urine smoking test (cotinine) at screening and/or admission (Day 2) will lead to exclusion

Exclusion criteria

Exclusion Criteria:

  • Participant having a history of or current medical illness including (but not limited to) cardiac arrhythmias or other cardiovascular disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), significant pulmonary disease, including bronchospastic respiratory disease, hepatic or renal insufficiency, type 1 diabetes mellitus, type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study result
  • Participant has taken any prescription or nonprescription medication (including vitamins and herbal supplements), except for acetaminophen, from 14 days before the first dose of the study drug is scheduled until completion of the study
  • Participant has received an experimental drug (including vaccines) or used an experimental medical device within 3 months or within a period less than 5 times the drug's half life, whichever is longer, prior to screening
  • Participant test positive for (HIV [positive serology for HIV antigen/antibody]), tests positive for virus surface antigen, or has antibodies to virus (HCV) at screening
  • Participant has had major surgery (example, requiring general anesthesia) within 4 months before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 6 months after study drug administration
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part 1: SAD (Cohort 1 to 3)

    Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.

    Drug: JNJ-64565111 · Drug: Placebo

  • Experimental
    Part 2: MAD (Cohort 4 to 6)

    Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.

    Drug: JNJ-64565111 · Drug: Placebo

  • Experimental
    Part 3: Single Dose (Cohort 7)

    Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.

    Drug: JNJ-64565111

Interventions

  • Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.

  • DrugPlacebo

    Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.

06

What researchers measure

Primary outcomes

  1. Part 1 and Part 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.

    Time frame: Up to Day 35

  2. Part 1: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111

    Cmax is defined as the maximum observed serum concentration.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  3. Part 1: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111

    Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  4. Part 1: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111

    AUC(0-Last) is defined as the AUC from time 0 to the time of the last measurable (non-below quantification limit \[non-BQL\]) serum concentration.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  5. Part 1: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111

    AUC (0-infinity) is defined as the area under the serum concentration-time curve from time zero to infinite time calculated as the sum of AUC(0-last) and Clast/ lambda (z); wherein AUC(0-last) is area under the serum concentration time curve from time zero to last measurable serum concentration, Clast is the last observed measurable (non-BQL) serum concentration, and lambda (z) is the apparent terminal elimination rate constant.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  6. Part 1: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111

    t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  7. Part 1: Apparent Volume of Distribution (V/F) of JNJ-64565111

    V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUC\[0-infinity\]).

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  8. Part 1: Total Apparent Clearance (CL/F) of JNJ-64565111

    CL/F is defined as the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUC\[0-infinity\].

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  9. Part 2: Number of Participants With AEs as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.

    Time frame: Up to Day 72

  10. Part 2: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111

    Cmax is defined as the maximum observed serum concentration.

    Time frame: Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

  11. Part 2: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111

    Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.

    Time frame: Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

  12. Part 2: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111

    t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).

    Time frame: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

  13. Part 2: Apparent Volume of Distribution (V/F) of JNJ-64565111

    V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUCtau).

    Time frame: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

  14. Part 2: Total Apparent Clearance (CL/F) of JNJ-64565111

    CL/F is the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUCtau.

    Time frame: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

  15. Part 2: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-64565111

    AUCtau is defined as the measure of the serum drug concentration from time zero to end of dosing interval.

    Time frame: Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: 72, 96, 144, 168 hours postdose

  16. Part 2: Observed Serum Concentration Just Prior to the Beginning or the End of a Dosing Interval (Ctrough) of JNJ-64565111

    Ctrough is defined as the observed serum concentration just prior to the beginning or the end of a dosing interval.

    Time frame: Day 8: Predose ; Day 15: Predose; Day 22: Predose, 168 hours postdose

  17. Part 2: Average Concentration Over the Dosing Interval Tau (T) at Steady State (Caverage,ss) of JNJ-64565111

    Caverage,ss is defined as area under the serum concentration time curve observed during a dosing interval (tau) at steady state) will be calculated as AUCtau/Tau.

    Time frame: Day 22: Predose, 72, 96, 144, 168 hours postdose

  18. Part 2: Observed Accumulation Index (AR-AUC) of JNJ-64565111

    AR-AUC is determined after multiple dose administration of JNJ-64565111 and calculated by using the equation: AUCtau, Day 22 divided by AUCtau, Day 1.

    Time frame: Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

Secondary outcomes

  1. Part 1 and 3: Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-64565111

    Number of participants with anti-drug antibodies (ADAs) to JNJ-64565111 will be reported.

    Time frame: Predose, 144 and 816 hours postdose

  2. Part 1 and Part 3: Change From Baseline in Body Weight

    Change from baseline in body weight will be reported.

    Time frame: Baseline to Day 35

  3. Part 1 and Part 3: Change from Baseline in Fasting Plasma Glucose (FPG) Levels

    Change from baseline in FPG levels will be reported.

    Time frame: Baseline to Day 35

  4. Part 1 and Part 3: Change From Baseline in Total Cholesterol

    Change from baseline in total cholesterol will be reported.

    Time frame: Baseline to Day 35

  5. Part 1 and Part 3: Change From Baseline in Low Density Lipoprotein- Cholesterol (LDL-C)

    Change from baseline in LDL-C will be reported.

    Time frame: Baseline to Day 35

  6. Part 1 and Part 3: Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

    Change from baseline in HDL-C will be reported.

    Time frame: Baseline to Day 35

  7. Part 1 and Part 3: Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C)

    Change from baseline in VLDL-C will be reported.

    Time frame: Baseline to Day 35

  8. Part 1 and Part 3: Change From Baseline in Triglycerides

    Change from baseline in Triglycerides will be reported.

    Time frame: Baseline to Day 35

  9. Part 1 and Part 3: Change From Baseline in Free Fatty Acids

    Change from baseline in free fatty acids will be reported.

    Time frame: Baseline to Day 35

  10. Part 2: Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-64565111

    Number of participants with ADAs to JNJ-64565111 will be reported.

    Time frame: Predose on Day 1, 8, 15, 22 and then at 144, 480, 720, 1200 hours postdose

  11. Part 2: Change From Baseline in Body Weight

    Change from baseline in body weight will be reported.

    Time frame: Baseline to Day 72

  12. Part 2: Change From Baseline in Fasting Plasma Glucose (FPG) Levels

    Change from baseline in FPG levels will be reported.

    Time frame: Baseline to Day 72

  13. Part 2: Change From Baseline in Total Cholesterol

    Change from baseline in total cholesterol will be reported.

    Time frame: Baseline to Day 72

  14. Part 2: Change From Baseline in Low Density Lipoprotein- Cholesterol (LDL-C)

    Change from baseline in LDL-C will be reported.

    Time frame: Baseline to Day 72

  15. Part 2: Change From Baseline in High-Density Lipoprotein-Choelsterol (HDL-C)

    Change from baseline in HDL-C will be reported.

    Time frame: Baseline to Day 72

  16. Part 2: Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C)

    Change from baseline in VLDL-C will be reported.

    Time frame: Baseline to Day 72

  17. Part 2: Change From Baseline in Triglycerides

    Change from baseline in triglycerides will be reported.

    Time frame: Baseline to Day 72

  18. Part 2: Change From Baseline in Free Fatty Acids

    Change from baseline in free fatty acids will be reported.

    Time frame: Baseline to Day 72

  19. Part 3: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111

    Cmax is defined as the maximum observed serum concentration.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  20. Part 3: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111

    Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  21. Part 3: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111

    AUC(0-Last) is defined as the AUC from time 0 to the time of the last measurable non-below quantification limit serum concentration.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  22. Part 3: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111

    AUC (0-infinity) is defined as the area under the serum concentration-time curve from time zero to infinite time calculated as the sum of AUC(0-last) and Clast/ lambda (z); wherein AUC(0-last) is area under the serum concentration time curve from time zero to last measurable serum concentration, Clast is the last observed measurable (non-BQL) serum concentration, and lambda (z) is the apparent terminal elimination rate constant.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  23. Part 3: Apparent Terminal Elimination Rate Constant (Lambda [z]) of JNJ-64565111

    Lambda (z) is the apparent terminal elimination rate-constant, estimated by linear regression using the terminal log linear phase of the log transformed concentration vs time curve.

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  24. Part 3:Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111

    t1/2 is defined the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  25. Part 3: Apparent Volume of Distribution (V/F) of JNJ-64565111

    V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUC\[0-infinity\]).

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

  26. Part 3: Total Apparent Clearance (CL/F) of JNJ-64565111

    CL/F is defined as the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUC\[0-infinity\].

    Time frame: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

07

Study locations

2 sites
  • Souseikai Hakata Clinic
    Fukuoka, 812-0025, Japan
  • Sumida Hospital
    Tokyo, 130-0004, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jun 2019, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2018
First posted
Aug 7, 2018
StartActual
Aug 6, 2018
Primary completionActual
Jun 21, 2019
CompletionActual
Jun 21, 2019
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03618160
Responsible party
Sponsor
First posted
Aug 7, 2018
Start date
Aug 6, 2018
Primary completion
Jun 21, 2019
Completion
Jun 21, 2019
Last update
Feb 3, 2025

Study contacts

Janssen Pharmaceutical K.K Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion